Daily Ards Research Analysis
Across ARDS/acute respiratory failure research, three studies stand out: a multicohort analysis identifying plasma soluble ST2 as a systemic biomarker predicting 30-day mortality and extrapulmonary organ dysfunction; a prospective randomized single-center study suggesting lateral-prone ventilation reduces mechanical power versus standard prone positioning; and a meta-analysis of pediatric RCTs reporting potential mortality benefit of pulmonary surfactant therapy, albeit with internal reporting i
Summary
Across ARDS/acute respiratory failure research, three studies stand out: a multicohort analysis identifying plasma soluble ST2 as a systemic biomarker predicting 30-day mortality and extrapulmonary organ dysfunction; a prospective randomized single-center study suggesting lateral-prone ventilation reduces mechanical power versus standard prone positioning; and a meta-analysis of pediatric RCTs reporting potential mortality benefit of pulmonary surfactant therapy, albeit with internal reporting inconsistencies.
Research Themes
- Systemic biomarkers and ARDS subphenotypes
- Ventilation strategies to mitigate ventilator-induced lung injury
- Pediatric ARDS therapeutics and evidence synthesis
Selected Articles
1. Plasma Levels of Soluble ST2 Reflect Extrapulmonary Organ Dysfunction and Predict Outcomes in Acute Respiratory Failure.
Across five multicenter ARF cohorts (n=1432), plasma sST2 was markedly higher than lower respiratory tract levels and weakly correlated between compartments, indicating a systemic source. Elevated plasma sST2 associated with extrapulmonary organ dysfunction and independently predicted 30-day mortality, especially within a hyperinflammatory subphenotype, but did not track hypoxemia or other respiratory indices.
Impact: This study advances prognostication in ARDS/ARF by linking sST2 to extrapulmonary organ dysfunction and mortality across diverse etiologies, highlighting IL-33/ST2 as a systemic target. Compartmental measurements clarify biomarker source and biology.
Clinical Implications: Plasma sST2 could enrich risk stratification and identify hyperinflammatory ARF subphenotypes for targeted trials. It also motivates exploration of IL-33/ST2 pathway modulation to prevent multiple organ dysfunction.
Key Findings
- Plasma sST2 levels were >19-fold higher than lower respiratory tract levels with weak intercompartment correlation.
- Higher plasma sST2 associated with extrapulmonary organ dysfunction and a hyperinflammatory ARF subphenotype.
- Plasma sST2 independently predicted 30-day mortality after adjustment for age, sex, and illness severity.
- sST2 was not associated with respiratory indices (e.g., hypoxemia), suggesting systemic rather than pulmonary origin.
Methodological Strengths
- Large, multicenter cohorts including both COVID-19 and non-COVID ARF etiologies.
- Paired biomarker measurements across plasma and lower respiratory tract compartments.
- Adjusted analyses for key confounders with longitudinal sampling.
Limitations
- Observational design limits causal inference and residual confounding is possible.
- Heterogeneity across cohorts and biospecimen availability may affect generalizability.
- Lack of interventional testing of IL-33/ST2 pathway.
Future Directions: Prospective trials using sST2 for enrichment and testing IL-33/ST2 pathway modulators; validation in ARDS-specific cohorts and integration with multi-omics subphenotyping.
OBJECTIVES: Soluble ST2 (sST2), a decoy receptor for the alarmin interleukin-33 (IL-33), has been implicated in adverse clinical outcomes in acute respiratory failure (ARF). We evaluated sST2 distribution across diverse cohorts of patients with different etiologies of ARF, compared plasma and lower respiratory tract (LRT) concentrations, and examined associations with individual organ dysfunction, biological subphenotypes, and outcomes. DESIGN: Observational study. SETTING: Multicenter cohorts of ARF patients. PATIENTS: A total of 1432 ARF patients, including 863 non-COVID and 569 COVID-19 cases, from five cohorts. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: sST2 levels were measured in plasma and LRT specimens (when available) and analyzed for associations with ARF etiology, severity, organ dysfunction, systemic host response, subphenotypes, and 30-day mortality. Plasma sST2 levels were higher in non-COVID ARF patients compared with COVID-19 patients ( p < 0.05) and were markedly elevated compared with LRT levels (> 19-fold), with weak intercompartmental correlation. Elevated plasma sST2 levels were associated with extrapulmonary organ dysfunction and a hyperinflammatory ARF subphenotype but not with respiratory indices, including hypoxemia. Plasma sST2 independently predicted 30-day mortality in pooled cohort data, adjusted for age, sex, and illness severity. In longitudinal measurements, nonsurvivors had persistently elevated plasma sST2 levels in the first 2 weeks of critical illness compared with survivors. CONCLUSIONS: Plasma sST2 levels independently predict outcomes in ARF and are strongly associated with extrapulmonary organ dysfunction. The weak correlation between plasma and LRT sST2 levels suggests a predominantly systemic source. These findings highlight the potential of the IL-33/ST2 axis as a therapeutic target and warrant further investigation into its role in multiple organ dysfunction in ARF.
2. Safety and efficacy of pulmonary surfactant therapy for acute respiratory distress syndrome in children: a systematic review and meta-analysis.
This meta-analysis of seven multicenter pediatric RCTs reports that surfactant therapy was associated with reduced mortality and adverse events and increased ventilator-free days, with no significant differences in ventilation duration or oxygenation index. Notably, the reported RRs >1 for mortality and adverse events contrast with the stated benefit, indicating internal reporting inconsistency.
Impact: Synthesizing pediatric RCTs on surfactant therapy addresses a long-standing uncertainty in PARDS management and could inform future guideline updates if findings are validated.
Clinical Implications: Surfactant may merit selective use or enrollment in trials for PARDS, but clinicians should interpret the reported effect sizes cautiously due to internal inconsistencies and seek patient-level evidence before changing practice.
Key Findings
- Seven multicenter RCTs in children (1 month–18 years) with ARDS/acute lung injury were included.
- Reported association with reduced mortality (stated) despite RR=1.50 (95% CI 1.11–2.01), indicating possible reporting direction error.
- Ventilator-free days increased (MD 1.20; 95% CI 0.24–2.15; p=0.01).
- Adverse events reportedly lower with PS, although RR=1.76 (95% CI 1.14–2.71) suggests inconsistency.
- No significant differences in mechanical ventilation duration or oxygenation index.
Methodological Strengths
- Focus on multicenter randomized controlled trials in the pediatric population.
- Comprehensive database search across Western and Chinese literature sources.
- Predefined primary and secondary outcomes including mortality and ventilator-free days.
Limitations
- Internal inconsistency between reported effect direction and RR values suggests potential data extraction or reporting errors.
- Total patient sample size and heterogeneity metrics are not detailed in the abstract.
- Unclear PRISMA adherence and risk-of-bias assessment details from the abstract.
- Findings limited to pediatric ARDS, potentially reducing generalizability.
Future Directions: Conduct an updated, PRISMA-compliant meta-analysis with individual patient data, clarify directionality errors, and design adequately powered multicenter RCTs testing standardized surfactant preparations and dosing in PARDS.
OBJECTIVE: Pulmonary surfactants (PSs) are generally known to be effective in treating newborns with acute respiratory distress syndrome (ARDS). However, their effectiveness in children remains controversial. The purpose of the current systematic review and meta-analysis was to assess the effectiveness and safety of PS in children. METHODS: A comprehensive search of the PubMed, EMBASE, Cochrane, CNKI, and Wanfang databases was conducted to identify publications up to December 2024. Only multicenter, randomized controlled trials involving children aged between 1 month and 18 years with acute lung injury or ARDS were included. The intervention group received PS treatment, whereas the control group received a placebo. The primary outcome measure was mortality rate, and secondary outcomes included days without mechanical ventilation, duration of mechanical ventilation, incidence of adverse events, and oxygenation index (OI). RESULTS: Seven articles met the inclusion criteria. The use of PS was associated with a significant reduction in the mortality rate (relative risk [RR] = 1.50, 95% confidence interval [CI] = 1.11-2.01, p = 0.008). In terms of secondary outcomes, there was an increase in the number of days without mechanical ventilation (mean difference = 1.20, 95% CI = 0.24-2.15, p = 0.01) and a lower incidence of adverse events (RR = 1.76, 95% CI = 1.14 to 2.71, p = 0.01) in the intervention group than in the control group, with no significant difference in mechanical ventilation duration (MD = -1.06, 95% CI = -3.47 to -1.35, p = 0.39) or OI (MD = -0.65, 95% CI = -3.48 to -2.19, p = 0.66). CONCLUSION: PS treatment was associated with a reduction in the mortality rate and incidence of adverse events in critically ill children with ARDS; however, the clinical impact of PS treatment warrants further research. TRIAL REGISTRATION: Not applicable.
3. The effects of different prone ventilation strategies on mechanical power and respiratory mechanics in acute respiratory distress syndrome patients: a prospective, single-center observational study.
In a randomized, single-center trial of 122 moderate-to-severe ARDS patients, lateral-prone ventilation significantly reduced mechanical power compared with traditional prone positioning, with comparable baseline characteristics and no significant differences in oxygenation indices. This physiologic benefit suggests potential to mitigate ventilator-induced lung injury risk.
Impact: Targeting mechanical power is a mechanistically grounded strategy to reduce VILI. Demonstrating a modifiable positional approach that lowers mechanical power offers a pragmatic pathway for bedside practice.
Clinical Implications: Lateral-prone positioning can be considered to lower mechanical power during prone ventilation in moderate-to-severe ARDS, pending validation in multicenter trials with patient-centered outcomes.
Key Findings
- Random allocation of 122 ARDS patients to prone vs lateral-prone strategies in a single-center, prospective study.
- Lateral-prone ventilation significantly reduced mechanical power compared with prone ventilation.
- Baseline characteristics and APACHE-II scores were comparable; no significant differences in oxygenation index (SpO2/FiO2) were observed.
Methodological Strengths
- Randomized allocation between positioning strategies.
- Objective physiologic endpoints including mechanical power and driving pressure.
- Prospective data collection with comparable baseline severity.
Limitations
- Single-center design with modest sample size limits generalizability.
- Abstract truncation leaves details on statistics, effect sizes, and secondary outcomes unclear.
- Short-term physiologic outcomes without patient-centered endpoints (e.g., mortality, ventilator-free days).
- Blinding and protocol adherence not described.
Future Directions: Multicenter, CONSORT-compliant RCTs powered for clinical outcomes to confirm benefits of lateral-prone positioning and define optimal selection criteria and timing.
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a common pathological condition among critically ill patients that often requires mechanical ventilation support. However, mechanical ventilation increases the risk of ventilator-induced lung injury (VILI). Different prone ventilation strategies may have varying effects on mechanical power (MP) and respiratory mechanics. This study aimed to compare the effects of prone ventilation and lateral-prone ventilation on MP and respiratory mechanics in ARDS patients to assess the relative risks of VILI associated with these strategies. METHODS: This prospective, single-center observational study employed a randomized trial. One hundred and twenty-two patients with moderate-to-severe ARDS admitted to the Department of Critical Care Medicine at Lishui Central Hospital between December 2021 and April 2024 were enrolled in this study. Patients were randomly assigned to receive either prone or lateral-prone ventilation strategies. The primary outcomes included MP, driving pressure (DP), static lung compliance (Cstat), airway resistance (Raw), the oxygenation index [i.e., the oxygen saturation to fraction of inspired oxygen (SpO RESULTS: The baseline characteristics of the patients, such as age, gender, and body mass index, were comparable between the two groups. No significant differences were found between the groups in terms of the Acute Physiology and Chronic Health Evaluation II (APACHE-II) score. No significant differences were observed in the SpO CONCLUSIONS: Compared to prone ventilation, lateral-prone ventilation significantly reduced MP in ARDS patients. The early adoption of lateral-prone ventilation may help mitigate the risk of VILI. This strategy holds clinical promise and warrants further validation and optimization.